SLC35A2 and cancer: Here we showed that TSA glucuronidation in UGT-positive cancer cells diminished TSA intracellular accumulation, broke NOQ1-triggered redox cycle, and consequently reduced TSA-induced ROS formation and its anti-cancer effect.